All Names: Ponatinib,lclusig,Ponaxen
Indications:Chronic Myeloid Leukemia (CML)
Manufacturer:Bayer heathcare AG, Germany
Customs Clearance Procedure:If the customs requires the package for customs clearance, please pay the customs clearance fee according to the content of EMS SMS and customs regulations.
INDICATIONS AND USAGE(适应症)
Iclusig is indicated for the treatment of adult patients with:
Chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to at least two prior kinase inhibitors.
Accelerated phase (AP) or blast phase (BP) CML or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other kinase inhibitors are indicated.
T315I-positive CML (chronic phase, accelerated phase, or blast phase) or T315I-positive Ph+ ALL.
DOSAGE(服用剂量)
CP-CML
The recommended starting dosage is 45 mg orally once daily with a reduction to 15 mg orally once daily upon achievement of ≤1% BCR-ABL1IS. Patients with loss of response can re-escalate the dose of Iclusig to a previously tolerated dosage of 30 mg or 45 mg orally once daily. Continue Iclusig until loss of response at the re-escalated dose or unacceptable toxicity.
Consider discontinuing Iclusig if hematologic response has not occurred by 3 months.
AP-CML, BP-CML, and Ph+ ALL
The optimal dose of Iclusig has not been identified.
The recommended starting dosage of Iclusig is 45 mg orally once daily. Consider reducing the dose of Iclusig for patients with accelerated phase (AP) CML who have achieved a major cytogenetic response. Continue Iclusig until loss of response or unacceptable toxicity.
Consider discontinuing Iclusig if response has not occurred by 3 months.
Administration
Advise patients of the following:
Iclusig may be taken with or without food.
Swallow tablets whole. Do not crush, break, cut or chew tablets.
If a dose is missed, take the next dose at the regularly scheduled time the next day.
ADVERSE REACTIONS(不良反应)
Arterial Occlusive Events
Venous Thromboembolic Events
Heart Failure
Hepatotoxicity
Hypertension
Pancreatitis
Neuropathy
Ocular Toxicity
Hemorrhage
Fluid Retention
Cardiac Arrhythmias
Myelosuppression
Tumor Lysis Syndrome
Reversible Posterior Leukoencephalopathy Syndrome
Impaired Wound Healing and Gastrointestinal Perforation
For full information, please refer to:
https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/16d804b6-4957-43ee-b18c-3b36ec37c5ac/spl-doc?hl=ponatinib
ponatinibinformation
No information yet!!!